Species-Specific Pharmacological Properties of Human α2A-Adrenoceptors
- 1 September 2000
- journal article
- other
- Published by Wolters Kluwer Health in Hypertension
- Vol. 36 (3) , 405-410
- https://doi.org/10.1161/01.hyp.36.3.405
Abstract
—On the basis of data obtained in rabbits, the imidazoline receptor ligand rilmenidine has been suggested to decrease blood pressure in humans by activating central α2A-adrenoceptors. A prerequisite for this hypothesis was the unproved assumption that rabbit and human α2A-adrenoceptors are equally activated by rilmenidine. Because α2A-adrenoceptors in the brain and on cardiovascular sympathetic nerve terminals are identical, the latter were used as a model for the former to confirm or disprove this assumption. Human atrial appendages and rabbit pulmonary arteries were used to determine the potencies of α2-adrenoceptor agonists in inhibiting the electrically (2 Hz) evoked [3H]norepinephrine release and of antagonists in counteracting the α2-adrenoceptor–mediated inhibition induced by moxonidine. In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the α2-autoreceptors, sharing this property with rauwolscine, phentolamine, and idazoxan. In contrast, prazosin is ineffective. In addition, a partial nucleotide and amino acid sequence of the rabbit α2A-adrenoceptor (a region known to substantially influence the pharmacological characteristics of the α2-adrenoceptor) revealed marked differences between the rabbit and the human α2A-adrenoceptor. The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with α2A-autoreceptors, at which, however, both rilmenidine and oxymetazoline exhibit different properties (antagonism and agonism, respectively). The antagonistic property of rilmenidine at human α2A-adrenoceptors indicates that in contrast to the suggestion based on rabbit data, the hypotensive property of the drug in humans is not due to activation of α2A-adrenoceptors but other, presumably I1-imidazoline receptors, are probably involved.Keywords
This publication has 19 references indexed in Scilit:
- Presynaptic cannabinoid and imidazoline receptors in the human heart and their potential relationshipNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1999
- Mechanism of the Sympathoinhibition Produced by the Clonidine‐Like Drugs Rilmenidine and MoxonidineAnnals of the New York Academy of Sciences, 1999
- Analysis of the receptor involved in the central hypotensive effect of rilmenidine and moxonidine.Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1999
- Ligand Efficacy and Potency at Recombinant α2 Adrenergic Receptors: Agonist-Mediated [35s]gtpγs BindingBiochemical Pharmacology, 1998
- A re-investigation of questionable subclassifications of presynaptic α2-autoreceptors: rat vena cava, rat atria, human kidney and guinea-pig urethraNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1997
- Inhibition of noradrenaline release via presynaptic 5-HT1Da receptors in human atriumNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1996
- α2c‐Adrenoceptor‐modulated release of noradrenaline in human right atriumBritish Journal of Pharmacology, 1995
- Regional Distribution of α2A‐and α2B‐Adrenoceptor Subtypes in Postmortem Human BrainJournal of Neurochemistry, 1992
- DNA sequencing with chain-terminating inhibitorsProceedings of the National Academy of Sciences, 1977
- The Classification of Adrenoceptors (Adrenergic Receptors). An Evaluation from the Standpoint of Receptor TheoryPublished by Springer Nature ,1972